Caricamento...
DIETARY SUPPLEMENT HYMECROMONE AND SORAFENIB: A NOVEL COMBINATION FOR THE CONTROL OF RENAL CELL CARCINOMA
PURPOSE: Current treatments for metastatic RCC (mRCC) do not extend survival beyond a few months. Sorafenib (SF) is a targeted drug approved for mRCC, but it has modest efficacy. Hymecromone is a nontoxic dietary supplement with some antitumor activity at high doses (450 – 3000 mg/day). HC inhibits...
Salvato in:
| Pubblicato in: | J Urol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2012
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5058418/ https://ncbi.nlm.nih.gov/pubmed/23228386 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2012.12.011 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|